Covid: AstraZeneca vaccine 79% effective with no increased blood clot risk – US trial

Status
Not open for further replies.

Northerner

Admin (Retired)
Relationship to Diabetes
Type 1
The Covid-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in preventing symptomatic illness in a large trial in the US, Chile and Peru, the company said on Monday, paving the way for it to apply for US approval.

The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

The data will give credence to the British vaccine after results from earlier, separate late-stage studies raised questions about the robustness of the data.

It will also help allay safety concerns that have disrupted its use in the EU after a small number of reports of rare blood clots in people who had received the jab.

 
The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.
The trials aren't usually big enough to have suitable power to say much about the less common outcomes, so take the "100%" with a pinch of salt. (Not saying the results aren't good news, obviously.)
 
Well, it must be nearly 100%. 32,000 cases is a fair number. Anything over a 32,000 to 1 chance is pretty rare, and almost certainly the same for any vaccination.
 
Well, it must be nearly 100%.
Yes, close to 100%. (I just worry sometimes with some politicians and others implying that it'll be completely safe to ignore any infection cases once the "vulnerable" have been vaccinated (sometimes just with a single dose of the two dose vaccines) because they'll then all be protected.)
 
Status
Not open for further replies.
Back
Top